We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+15.97%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$238M
AUM Growth
-$2.1M
Cap. Flow
+$3M
Cap. Flow %
1.26%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$19.9M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$69.9M 29.35%
1,457,300
-430,178
-23% -$16.9M
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$61.9M 25.99%
19,963,157
– –
AURA icon
3
Aura Biosciences
AURA
$725M
$31.9M 13.41%
3,039,892
– –
PHAT icon
4
Phathom Pharmaceuticals
PHAT
$708M
$27.9M 11.71%
2,484,274
– –
MRUS
5
DELISTED
Merus
MRUS
$24.8M 10.4%
1,600,000
– –
NAMS icon
6
NewAmsterdam Pharma
NAMS
$3.25B
$21.8M 9.16%
+2,000,000
New +$19.9M

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q4 2022 Portfolio in Review

As of Q4 2022, Medicxi Ventures Management held 6 positions worth $238M, down 0.87% from $240M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management's Q4 2022 filing shows 1 new and 1 reduced positions. Its largest new stake was NewAmsterdam Pharma: 2,000,000 shares worth $21.8M. The largest sale was Vaxcyte, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's largest Q4 2022 buy was NewAmsterdam Pharma: 2,000,000 shares worth $21.8M.
  • Medicxi Ventures Management's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $16.9M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $238M portfolio in Q4 2022.
  • Medicxi Ventures Management opened 1 new position and closed 0 in Q4 2022.
  • Medicxi Ventures Management's portfolio value fell 0.87% quarter-over-quarter to $238M.

Based on Medicxi Ventures Management's 13F filing for Q4 2022, filed 31 Jan 2023.